Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Advanced Therapies Week 2022 | Evaluating the development of iSPC-derived MSCs

Tony Ting • 26 Jan 2022
Advanced Therapies Week 2022
General

Tony Ting, PhD, Bone Therapeutics SA, Gosselies, Belgium, provides an overview of the collaboration between Bone Therapeutics and Implant Therapeutics to research the differentiation of induced pluripotent stem cells (iPSCs) into mesenchymal stem cells (MSCs), as well as develop genetically engineered iPSC-derived MSCs. This interview took place at Advanced Therapies Week 2022.

Disclosures

Tony Ting, PhD, is an employee of Bone Therapeutics.

More from Tony Ting

0:44
Addressing issues associated with bringing iSPC-derived MSCs to the clinic
Tony Ting • 26 Jan 2022
1:48
Enhancing the therapeutic capacity of MSCs
Tony Ting • 26 Jan 2022

Related Videos

0:55
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers
Jürgen Kuball • 10 Feb 2023
1:26
Rapid CAR-T manufacturing and challenges in this space
Nina Worel • 9 Feb 2023
1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
2:08
Streamlining cell therapy manufacturing with CliniMACS Prodigy
Saskia Rösch • 6 Apr 2022
The content of VJRegenMed is intended for healthcare professionals